Inivata, a global clinical cancer genomics company, is employing the precision of circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology. Using a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.
Inivata's proprietary technology is based on pioneering research from the Rosenfeld Lab at Cancer Research (CRUK), Cambridge. Inivata’s platform brings together Next-Generation Sequencing (NGS) technology, proprietary algorithms, and databases that correlate genomic profiles to actual clinical outcomes.